

# Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

## Rabbit Anti-beta-Tubulin Monoclonal Antibody, HRP Conjugated, Clone 9F3

RRID:AB\_1950376

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 5346, RRID:AB\_1950376

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_1950376](http://antibodyregistry.org/AB_1950376)

**Proper Citation:** Cell Signaling Technology Cat# 5346, RRID:AB\_1950376

**Target Antigen:** beta-Tubulin

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** Applications: W. Consolidation on 11/2018: AB\_10694412, AB\_1950376.

**Antibody Name:** Rabbit Anti-beta-Tubulin Monoclonal Antibody, HRP Conjugated, Clone 9F3

**Description:** This monoclonal targets beta-Tubulin

**Target Organism:** chicken, monkey, chickenavian, rat, simian, mouse, fish, bovine, zebrafish, human

**Clone ID:** Clone 9F3

**Antibody ID:** AB\_1950376

**Vendor:** Cell Signaling Technology

**Catalog Number:** 5346

**Record Creation Time:** 20250819T214701+0000

**Record Last Update:** 20250820T000457+0000

---

### Ratings and Alerts

No rating or validation information has been found for Rabbit Anti-beta-Tubulin Monoclonal Antibody, HRP Conjugated, Clone 9F3.

No alerts have been found for Rabbit Anti-beta-Tubulin Monoclonal Antibody, HRP Conjugated, Clone 9F3.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 26 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#).

Zacharias NM, et al. (2025) Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. *Molecular cancer therapeutics*.

Zengeler KE, et al. (2025) Inflammasome signaling in astrocytes modulates hippocampal plasticity. *Immunity*, 58(6), 1519.

Shemorry A, et al. (2025) Engineering ER $\gamma$  degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases. *Cell chemical biology*, 32(5), 694.

Xiang RR, et al. (2025) CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. *Cell reports*, 44(2), 115312.

Liu B, et al. (2024) snoRNA-facilitated protein secretion revealed by transcriptome-wide snoRNA target identification. *Cell*.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. *Cancer cell*.

Liu C, et al. (2023) Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma. *iScience*, 26(8), 107369.

Adachi H, et al. (2023) Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes. *Molecular cell*, 83(4), 637.

Glück IM, et al. (2023) Nanoscale organization of the endogenous ASC speck. *iScience*, 26(12), 108382.

Duan S, et al. (2023) Clinically Defined Mutations in MEN1 Alter Its Tumor-suppressive Function Through Increased Menin Turnover. *Cancer research communications*, 3(7), 1318.

Mansilla SF, et al. (2023) Polymerase iota (Pol  $\epsilon$ ) prevents PrimPol-mediated nascent DNA synthesis and chromosome instability. *Science advances*, 9(15), eade7997.

Khandker L, et al. (2022) Cholesterol biosynthesis defines oligodendrocyte precursor heterogeneity between brain and spinal cord. *Cell reports*, 38(9), 110423.

Wang Y, et al. (2022) Saturation of the mitochondrial NADH shuttles drives aerobic glycolysis in proliferating cells. *Molecular cell*, 82(17), 3270.

Peterson-Reynolds C, et al. (2022) Differential ER stress as a driver of cell fate following ricin toxin exposure. *FASEB bioAdvances*, 4(1), 60.

Toyomoto M, et al. (2021) S1PR3-G12-biased agonist ALESIA targets cancer metabolism and promotes glucose starvation. *Cell chemical biology*, 28(8), 1132.

Yan P, et al. (2021) LARP7 ameliorates cellular senescence and aging by allosterically enhancing SIRT1 deacetylase activity. *Cell reports*, 37(8), 110038.

Ho JS, et al. (2021) HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. *eLife*, 10.

Ho JSY, et al. (2021) TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. *Cell*, 184(10), 2618.

Zhang F, et al. (2020) L ARP7 Is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis. *Cell reports*, 32(4), 107974.

Phu L, et al. (2020) Dynamic Regulation of Mitochondrial Import by the Ubiquitin System. *Molecular cell*, 77(5), 1107.